1. Home
  2. IOT vs BIIB Comparison

IOT vs BIIB Comparison

Compare IOT & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Samsara Inc.

IOT

Samsara Inc.

HOLD

Current Price

$41.41

Market Cap

22.8B

Sector

Technology

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$174.28

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IOT
BIIB
Founded
2015
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.8B
24.2B
IPO Year
2021
1991

Fundamental Metrics

Financial Performance
Metric
IOT
BIIB
Price
$41.41
$174.28
Analyst Decision
Buy
Buy
Analyst Count
11
22
Target Price
$50.36
$177.40
AVG Volume (30 Days)
5.8M
2.0M
Earning Date
12-04-2025
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
10.97
Revenue
$1,520,629,000.00
$10,065,900,000.00
Revenue This Year
$27.68
$3.61
Revenue Next Year
$20.63
N/A
P/E Ratio
N/A
$15.86
Revenue Growth
28.96
4.77
52 Week Low
$31.40
$110.04
52 Week High
$61.90
$185.17

Technical Indicators

Market Signals
Indicator
IOT
BIIB
Relative Strength Index (RSI) 53.28 55.41
Support Level $36.88 $169.24
Resistance Level $45.50 $180.79
Average True Range (ATR) 1.95 5.36
MACD 0.52 -1.56
Stochastic Oscillator 45.43 33.70

Price Performance

Historical Comparison
IOT
BIIB

About IOT Samsara Inc.

Samsara Inc provides an end-to-end solution for operations. The company's Connected Operations Platform consolidates data from its IoT devices and a growing ecosystem of connected assets and third-party systems, and makes it easy for organizations to access, analyze, and act on data insights using its cloud dashboard, custom alerts and reports, mobile apps, and workflows.. The company derives almost all of its revenue from subscription services. Geographically, it derives a majority of its revenue from the United States. The company's customers ranges from small and medium-sized businesses to state and local governments.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: